Newsreels 2024 ASH Annual Meeting & Exposition Burdens and QOL Impacts of Anemia and Transfusion Dependence in Myelofibrosis Lindsey E... December 19, 2024
Newsreels 2024 ASH Annual Meeting & Exposition Combination Interferon and Ruxolitinib vs Ruxolitinib in Myelofibrosis Lindsey E... December 19, 2024
Newsreels 2024 ASH Annual Meeting & Exposition Real-World Outcomes of Momelotinib as a Therapy Option in Myelofibrosis Patients With Anemia Lindsey E... December 19, 2024
Newsreels 2024 ASH Annual Meeting & Exposition Axatilimab for Chronic Graft-vs.-Host Disease Katie Sellers, MPAS, PA-C, reviews findings from the Agave-201 study presented at the ASH Annual Meeting, which evaluated axatilimab, an anti-CSF1R monoclonal antibody, in chronic graft-versus-host disease ( December 23, 2024
Newsreels 2024 ASH Annual Meeting & Exposition GVHD Prophylaxis: Ruxolitinib and De-escalated PTCy for Older Patients Katie Sellers, MPAS, PA-C, discusses a phase II trial presented at the ASH Annual Meeting exploring de-escalated post-transplant cyclophosphamide (PTCy) with ruxolitinib for GVHD prophylaxis in older patients undergoing reduced intensity conditioning allogeneic hematopoietic cell transplant ( December 26, 2024
Newsreels 2024 ASH Annual Meeting & Exposition PTCy is Standard of Care: Improved GVHD Control and Survival in Older Patients Katie Sellers, MPAS, PA-C, considers a post-hoc analysis focusing on transplant recipients aged ≥70 years in the BMT CTN 1703 trial ( December 26, 2024
